Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference.
Enochian BioSciences’ Executive Vice Chair, Dr. Mark Dybul, will be presenting to a live virtual audience on Tuesday, September 15, 2020 at 2:00 pm Eastern, and will be participating in one-on-one meetings with investors who are registered to attend the conference. A link to the live and archived webcast may be accessed on Enochian’s website under the Investors/Media section in Events and Presentations.
More information on the conference may be found at H.C. Wainwright’s conference website.
About Enochian BioSciences Inc.
Leverage Data for New Profit Centers